CONTRACT AWARD NOTICE – NATIONAL

1 Authority Details

1.1

Authority Name and Address

2 Contract Details

2.1

Title

Provision of the Oncotype DX Breast Recurrence Score Test for use within Cancer Services.

2.2

Description of the contract

The Oncotype DX Breast Recurrence Score Test provides a genomic-based risk assessment for early-stage invasive breast cancer in the adjuvant setting. The test provides information of distance recurrence, the benefit from chemotherapy and whether a patient can be treated effectively with hormonal therapy alone.

NICE have recommended Oncotype in the node negative setting. Local audits have suggested that use of Oncotype reduces chemotherapy use by about one third in the target population.

2.3

Notice Coding and Classification

2.4

Estimated Total Value

3 Procedure

3.1

Type of Procedure

4 Award of Contract

4.1

Successful Bidders

4.1.1

Name and Address of successful supplier, contractor or service provider

5 Other Information

5.1

Reference number attributed to the notice by the contracting authority

SBU-DCO-017-RC-26

5.2

Date of Contract Award

5.3

Number of tenders received

1

5.4

Other Information

For continuity of service, this contract is to be renewed through a direct award under the terms and conditions of the NHS SC Laboratory Diagnostics, Point of Care Testing and Pathology Managed Service 2023/S 000-0288931, which offers a compliant route to market.

(WA Ref:168158)

5.5

Additional Documentation

5.6

Publication date of this notice: